Compare Marqeta Inc (MQ) vs 10X Genomics Inc (TXG) Price & Performance

MQ trades at $17.44, down slightly by 0.29% today. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Recent financials reveal revenue growth to $624.88M in 2025, but profitability remains weak with a net margin of -2.23%. The company's expansion into Europe with Expensify and a recent 4:1 reverse stock split are key developments. Analyst consensus is a 'Buy' with a $19.00 price target, indicating modest upside potential.

MQ presents a cautious opportunity with growth initiatives offset by profitability challenges. The stock's high P/E of 439 reflects investor optimism on future earnings, but thin margins and inconsistent quarterly results pose risks. Upside depends on successful execution of European expansion and sustained revenue growth, while downside risks include competitive pressures and failure to achieve profitability. Institutional sentiment is mixed, with 59% of analysts recommending 'Hold'.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.